Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS
CONCLUSION: Extended treatment with darolutamide was well tolerated and no new safety signals were observed. Most ARi-associated and androgen-suppressive treatment-related TEAEs occurred at low incidences with darolutamide, were similar to placebo, and showed minimal increase over time with continued treatment.TRIAL NUMBER: ClinicalTrials.gov identifier NCT02200614.PMID:38394384 | DOI:10.1093/oncolo/oyae019 (Source: The Oncologist)
Source: The Oncologist - February 23, 2024 Category: Cancer & Oncology Authors: Neal D Shore Christian Gratzke Susan Feyerabend Patrick Werbrouck Joan Carles Egils Vjaters Teuvo L J Tammela David Morris Jeanny B Aragon-Ching Raoul S Concepcion Urban Emmenegger Neil Fleshner Markus Grabbert Vilnis Lietuvietis Hakim Mahammedi Felipe M Source Type: research

Adherence to Treatment and Follow-Up of Precancerous Cervical Lesions in Ethiopia
CONCLUSION: Our results revealed that adherence to treatment after VIA positive screening is relatively high whereas adherence to follow up recommendations still needs improvement. Reminders like appointment cards and phone calls can effectively reduce the loss of follow-up.PMID:38394385 | DOI:10.1093/oncolo/oyae027 (Source: The Oncologist)
Source: The Oncologist - February 23, 2024 Category: Cancer & Oncology Authors: Clara Yolanda Stroetmann Muluken Gizaw Rahel Alemayehu Abigiya Wondimagegnehu Friedemann Rabe Pablo Santos Bariki Mchome Blandina Theophil Mmbaga Adamu Addissie Eva Johanna Kantelhardt Source Type: research

A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX
Oncologist. 2024 Feb 23:oyad315. doi: 10.1093/oncolo/oyad315. Online ahead of print.ABSTRACTHomologous recombination repair (HRR) pathway deficiency opens multiple therapeutic avenues within pancreatic cancer. Patients with HRR deficiency-associated gene mutations such as BRCA1, BRCA2, and PALB2 are more susceptible to platinum-based chemotherapies and in those with somatic BRCA mutations, PARP inhibitor therapy prolongs progression-free survival. The case discussed herein illustrates the therapeutic opportunities offered through the identification of HRR deficiency in pancreatic cancer, as well as the challenges associate...
Source: The Oncologist - February 23, 2024 Category: Cancer & Oncology Authors: Jacob K Jamison Michael S May Alexander G Raufi Lyndon Luk Winston Wong Prabhjot S Mundi Gulam A Manji Source Type: research

Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS
CONCLUSION: Extended treatment with darolutamide was well tolerated and no new safety signals were observed. Most ARi-associated and androgen-suppressive treatment-related TEAEs occurred at low incidences with darolutamide, were similar to placebo, and showed minimal increase over time with continued treatment.TRIAL NUMBER: ClinicalTrials.gov identifier NCT02200614.PMID:38394384 | DOI:10.1093/oncolo/oyae019 (Source: The Oncologist)
Source: The Oncologist - February 23, 2024 Category: Cancer & Oncology Authors: Neal D Shore Christian Gratzke Susan Feyerabend Patrick Werbrouck Joan Carles Egils Vjaters Teuvo L J Tammela David Morris Jeanny B Aragon-Ching Raoul S Concepcion Urban Emmenegger Neil Fleshner Markus Grabbert Vilnis Lietuvietis Hakim Mahammedi Felipe M Source Type: research

Adherence to Treatment and Follow-Up of Precancerous Cervical Lesions in Ethiopia
CONCLUSION: Our results revealed that adherence to treatment after VIA positive screening is relatively high whereas adherence to follow up recommendations still needs improvement. Reminders like appointment cards and phone calls can effectively reduce the loss of follow-up.PMID:38394385 | DOI:10.1093/oncolo/oyae027 (Source: The Oncologist)
Source: The Oncologist - February 23, 2024 Category: Cancer & Oncology Authors: Clara Yolanda Stroetmann Muluken Gizaw Rahel Alemayehu Abigiya Wondimagegnehu Friedemann Rabe Pablo Santos Bariki Mchome Blandina Theophil Mmbaga Adamu Addissie Eva Johanna Kantelhardt Source Type: research

A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX
Oncologist. 2024 Feb 23:oyad315. doi: 10.1093/oncolo/oyad315. Online ahead of print.ABSTRACTHomologous recombination repair (HRR) pathway deficiency opens multiple therapeutic avenues within pancreatic cancer. Patients with HRR deficiency-associated gene mutations such as BRCA1, BRCA2, and PALB2 are more susceptible to platinum-based chemotherapies and in those with somatic BRCA mutations, PARP inhibitor therapy prolongs progression-free survival. The case discussed herein illustrates the therapeutic opportunities offered through the identification of HRR deficiency in pancreatic cancer, as well as the challenges associate...
Source: The Oncologist - February 23, 2024 Category: Cancer & Oncology Authors: Jacob K Jamison Michael S May Alexander G Raufi Lyndon Luk Winston Wong Prabhjot S Mundi Gulam A Manji Source Type: research

Palliative care interventions and end-of-life care for patients with metastatic breast cancer: a multicentre analysis
CONCLUSION: PC team integration was frequent and late for patients with metastatic breast cancer. However, PC intervention > 30 days is associated with less chemotherapy in the last month before death. Further studies are needed to better understand how to implement a more effective mode of PC integration for patients with metastatic breast cancer.PMID:38387031 | DOI:10.1093/oncolo/oyae023 (Source: The Oncologist)
Source: The Oncologist - February 22, 2024 Category: Cancer & Oncology Authors: Elisabeth Lucchi Fr édérique Berger Maude Milder Jean-Marie Commer Sophie Morin Geraldine Capodano Muriel Thomaso Anne Fogliarini Nathalie Bremaud Aline Henry Benedicte Mastroianni Gisele Chvetzoff Carole Bouleuc Source Type: research

Anaplastic Lymphoma Kinase (ALK) Inhibitors Show Activity in Colorectal Cancer With ALK Rearrangements: Case Series and Literature Review
In this report, we describe 2 cases of ALK-positive CRC, both of which benefited from ALK tyrosine kinase inhibitor (ALK-TKI) therapy. Case 1 was a postoperative patient with poorly differentiated colon adenocarcinoma, who was diagnosed with metastatic relapse shortly after surgery. Both fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and bevacizumab combined with 5-fluorouracil, l-leucovorin, and irinotecan (FOLFIRI) proved ineffective against the disease. The patient was then treated with ensartinib, as the CAD-ALK fusion gene was detected by genomic analysis. The patient was initially treated with ensartinib monother...
Source: The Oncologist - February 21, 2024 Category: Cancer & Oncology Authors: Tingting Hu Jinbo Zhan Li Li Yan He Yun Lin Jingru Wang Haiming Yu Jianping Xiong Ziling Fang Jun Deng Shanshan Huang Xiaojun Xiang Source Type: research

Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches
Oncologist. 2024 Feb 21:oyae029. doi: 10.1093/oncolo/oyae029. Online ahead of print.ABSTRACTAdrenocortical carcinoma (ACC) is a rare and aggressive malignancy in the advanced setting with poor prognosis. This narrative review provides an overview of the epidemiology of ACC and its molecular pathogenesis with a summary of the main involved signaling pathways. We then provide an update on the clinical presentation, diagnosis, and current management strategies of both localized and metastatic disease from a multidisciplinary perspective. We highlight the debate around the use of mitotane in the adjuvant setting and review the...
Source: The Oncologist - February 21, 2024 Category: Cancer & Oncology Authors: Divya Chukkalore Kira MacDougall Viraj Master Mehmet Asim Bilen Bassel Nazha Source Type: research

Anaplastic Lymphoma Kinase (ALK) Inhibitors Show Activity in Colorectal Cancer With ALK Rearrangements: Case Series and Literature Review
In this report, we describe 2 cases of ALK-positive CRC, both of which benefited from ALK tyrosine kinase inhibitor (ALK-TKI) therapy. Case 1 was a postoperative patient with poorly differentiated colon adenocarcinoma, who was diagnosed with metastatic relapse shortly after surgery. Both fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and bevacizumab combined with 5-fluorouracil, l-leucovorin, and irinotecan (FOLFIRI) proved ineffective against the disease. The patient was then treated with ensartinib, as the CAD-ALK fusion gene was detected by genomic analysis. The patient was initially treated with ensartinib monother...
Source: The Oncologist - February 21, 2024 Category: Cancer & Oncology Authors: Tingting Hu Jinbo Zhan Li Li Yan He Yun Lin Jingru Wang Haiming Yu Jianping Xiong Ziling Fang Jun Deng Shanshan Huang Xiaojun Xiang Source Type: research

Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches
Oncologist. 2024 Feb 21:oyae029. doi: 10.1093/oncolo/oyae029. Online ahead of print.ABSTRACTAdrenocortical carcinoma (ACC) is a rare and aggressive malignancy in the advanced setting with poor prognosis. This narrative review provides an overview of the epidemiology of ACC and its molecular pathogenesis with a summary of the main involved signaling pathways. We then provide an update on the clinical presentation, diagnosis, and current management strategies of both localized and metastatic disease from a multidisciplinary perspective. We highlight the debate around the use of mitotane in the adjuvant setting and review the...
Source: The Oncologist - February 21, 2024 Category: Cancer & Oncology Authors: Divya Chukkalore Kira MacDougall Viraj Master Mehmet Asim Bilen Bassel Nazha Source Type: research

Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial
CONCLUSIONS: Interim results provide further evidences about safety and efficacy profile of atezolizumab + carboplatin/etoposide treatment in a ES-SCLC patient population closer to that observed in clinical practice.CLINICAL TRIAL REGISTRATION: Eudract No. 2019-001146-17, NCT04028050.PMID:38377176 | DOI:10.1093/oncolo/oyad342 (Source: The Oncologist)
Source: The Oncologist - February 20, 2024 Category: Cancer & Oncology Authors: Emilio Bria Floriana Morgillo Marina Chiara Garassino Fortunato Ciardiello Andrea Ardizzoni Alessio Stefani Francesco Verderame Alessandro Morabito Antonio Chella Giuseppe Tonini Marina Gilli Ester Del Signore Rossana Berardi Manlio Mencoboni Alessandra B Source Type: research

Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial
CONCLUSIONS: Interim results provide further evidences about safety and efficacy profile of atezolizumab + carboplatin/etoposide treatment in a ES-SCLC patient population closer to that observed in clinical practice.CLINICAL TRIAL REGISTRATION: Eudract No. 2019-001146-17, NCT04028050.PMID:38377176 | DOI:10.1093/oncolo/oyad342 (Source: The Oncologist)
Source: The Oncologist - February 20, 2024 Category: Cancer & Oncology Authors: Emilio Bria Floriana Morgillo Marina Chiara Garassino Fortunato Ciardiello Andrea Ardizzoni Alessio Stefani Francesco Verderame Alessandro Morabito Antonio Chella Giuseppe Tonini Marina Gilli Ester Del Signore Rossana Berardi Manlio Mencoboni Alessandra B Source Type: research

Comparing Drug Shortages Experienced by Institutions With National Metrics
This article describes the reasons for conflicting information from different sources.PMID:38366856 | DOI:10.1093/oncolo/oyad350 (Source: The Oncologist)
Source: The Oncologist - February 17, 2024 Category: Cancer & Oncology Authors: Austin Pytlowany Noah Leja Stanley Kent Source Type: research

Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review
Oncologist. 2024 Feb 16:oyae007. doi: 10.1093/oncolo/oyae007. Online ahead of print.ABSTRACTWe performed a systematic literature review to identify and summarize data from studies reporting clinical efficacy and safety outcomes for trifluridine/tipiracil (FTD/TPI) combined with other antineoplastic agents in advanced cancers, including metastatic colorectal cancer (mCRC). We conducted a systematic search on May 29, 2021, for studies reporting one or more efficacy or safety outcome with FTD/TPI-containing combinations. Our search yielded 1378 publications, with 38 records meeting selection criteria: 35 studies of FTD/TPI-co...
Source: The Oncologist - February 17, 2024 Category: Cancer & Oncology Authors: Kohei Shitara Alfred Falcone Marwan G Fakih Ben George Raghav Sundar Sandip Ranjan Eric Van Cutsem Source Type: research